TY - JOUR
T1 - Atherosclerotic Plaque Epigenetic Age Acceleration Predicts a Poor Prognosis and Is Associated With Endothelial-to-Mesenchymal Transition in Humans
AU - Benavente, Ernest Diez
AU - Hartman, Robin J G
AU - Sakkers, Tim R
AU - Wesseling, Marian
AU - Sloots, Yannicke
AU - Slenders, Lotte
AU - Boltjes, Arjan
AU - Mol, Barend M
AU - de Borst, Gert J
AU - de Kleijn, Dominique P V
AU - Prange, Koen H M
AU - de Winther, Menno P J
AU - Kuiper, Johan
AU - Civelek, Mete
AU - van der Laan, Sander W
AU - Horvath, Steve
AU - Onland-Moret, Charlotte
AU - Mokry, Michal
AU - Pasterkamp, Gerard
AU - den Ruijter, Hester M
PY - 2024/6
Y1 - 2024/6
N2 - BACKGROUND: Epigenetic age estimators (clocks) are predictive of human mortality risk. However, it is not yet known whether the epigenetic age of atherosclerotic plaques is predictive for the risk of cardiovascular events.METHODS: Whole-genome DNA methylation of human carotid atherosclerotic plaques (n=485) and of blood (n=93) from the Athero-Express endarterectomy cohort was used to calculate epigenetic age acceleration (EAA). EAA was linked to clinical characteristics, plaque histology, and future cardiovascular events (n=136). We studied whole-genome DNA methylation and bulk and single-cell transcriptomics to uncover molecular mechanisms of plaque EAA. We experimentally confirmed our in silico findings using in vitro experiments in primary human coronary endothelial cells.RESULTS: Male and female patients with severe atherosclerosis had a median chronological age of 69 years. The median epigenetic age was 65 years in females (median EAA, -2.2 [interquartile range, -4.3 to 2.2] years) and 68 years in males (median EAA, -0.3 [interquartile range, -2.9 to 3.8] years). Patients with diabetes and a high body mass index had higher plaque EAA. Increased EAA of plaque predicted future events in a 3-year follow-up in a Cox regression model (univariate hazard ratio, 1.7;
P=0.0034) and adjusted multivariate model (hazard ratio, 1.56;
P=0.02). Plaque EAA predicted outcome independent of blood EAA (hazard ratio, 1.3;
P=0.018) and of plaque hemorrhage (hazard ratio, 1.7;
P=0.02). Single-cell RNA sequencing in plaque samples from 46 patients in the same cohort revealed smooth muscle and endothelial cells as important cell types in plaque EAA. Endothelial-to-mesenchymal transition was associated with EAA, which was experimentally confirmed by
TGFβ-triggered endothelial-to-mesenchymal transition inducing rapid epigenetic aging in coronary endothelial cells.
CONCLUSIONS: Plaque EAA is a strong and independent marker of poor outcome in patients with severe atherosclerosis. Plaque EAA was linked to mesenchymal endothelial and smooth muscle cells. Endothelial-to-mesenchymal transition was associated with EAA, which was experimentally validated. Epigenetic aging mechanisms may provide new targets for treatments that reduce atherosclerosis complications.
AB - BACKGROUND: Epigenetic age estimators (clocks) are predictive of human mortality risk. However, it is not yet known whether the epigenetic age of atherosclerotic plaques is predictive for the risk of cardiovascular events.METHODS: Whole-genome DNA methylation of human carotid atherosclerotic plaques (n=485) and of blood (n=93) from the Athero-Express endarterectomy cohort was used to calculate epigenetic age acceleration (EAA). EAA was linked to clinical characteristics, plaque histology, and future cardiovascular events (n=136). We studied whole-genome DNA methylation and bulk and single-cell transcriptomics to uncover molecular mechanisms of plaque EAA. We experimentally confirmed our in silico findings using in vitro experiments in primary human coronary endothelial cells.RESULTS: Male and female patients with severe atherosclerosis had a median chronological age of 69 years. The median epigenetic age was 65 years in females (median EAA, -2.2 [interquartile range, -4.3 to 2.2] years) and 68 years in males (median EAA, -0.3 [interquartile range, -2.9 to 3.8] years). Patients with diabetes and a high body mass index had higher plaque EAA. Increased EAA of plaque predicted future events in a 3-year follow-up in a Cox regression model (univariate hazard ratio, 1.7;
P=0.0034) and adjusted multivariate model (hazard ratio, 1.56;
P=0.02). Plaque EAA predicted outcome independent of blood EAA (hazard ratio, 1.3;
P=0.018) and of plaque hemorrhage (hazard ratio, 1.7;
P=0.02). Single-cell RNA sequencing in plaque samples from 46 patients in the same cohort revealed smooth muscle and endothelial cells as important cell types in plaque EAA. Endothelial-to-mesenchymal transition was associated with EAA, which was experimentally confirmed by
TGFβ-triggered endothelial-to-mesenchymal transition inducing rapid epigenetic aging in coronary endothelial cells.
CONCLUSIONS: Plaque EAA is a strong and independent marker of poor outcome in patients with severe atherosclerosis. Plaque EAA was linked to mesenchymal endothelial and smooth muscle cells. Endothelial-to-mesenchymal transition was associated with EAA, which was experimentally validated. Epigenetic aging mechanisms may provide new targets for treatments that reduce atherosclerosis complications.
KW - Age Factors
KW - Aged
KW - Carotid Artery Diseases/genetics
KW - Cells, Cultured
KW - DNA Methylation
KW - Endothelial Cells/pathology
KW - Epigenesis, Genetic
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Plaque, Atherosclerotic
KW - Prognosis
KW - Risk Assessment
KW - Risk Factors
UR - https://www.mendeley.com/catalogue/5e55f36c-6472-34ca-9a12-7359d4eaac92/
U2 - 10.1161/ATVBAHA.123.320692
DO - 10.1161/ATVBAHA.123.320692
M3 - Article
C2 - 38634280
SN - 1079-5642
VL - 44
SP - 1419
EP - 1431
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
IS - 6
ER -